Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway.

Endocr Rev · 2025 · PMC12063102 · PMID 39929239

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantP = 0.06so close (0.05 < p ≤ 0.1)

Preliminary results of a phase 2 RCT, including 12 children and adults, were recently published in a conference paper, demonstrating a borderline significant decrease of BMI%P95 from 133.5% ± 19.9 to 124.7% ± 18.6 ( P = 0.06).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.